Trinity Biotech plc (NASDAQ:TRIB) rose 6.3% during trading on Wednesday . The stock traded as high as $4.12 and last traded at $4.07. Approximately 133,339 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 303,630 shares. The stock had previously closed at $3.83.

Separately, ValuEngine raised Trinity Biotech from a “sell” rating to a “hold” rating in a research report on Friday, November 27th.

The firm has a market capitalization of $97.84 million, a P/E ratio of -4.73 and a beta of 1.49. The company has a quick ratio of 1.50, a current ratio of 2.89 and a debt-to-equity ratio of 107.01. The business has a 50-day moving average price of $4.19 and a 200-day moving average price of $2.87.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings data on Monday, November 16th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.22. The business had revenue of $32.01 million for the quarter. Trinity Biotech had a positive return on equity of 7.55% and a negative net margin of 32.47%.

Hedge funds have recently made changes to their positions in the stock. Wealthsource Partners LLC acquired a new stake in Trinity Biotech in the 2nd quarter valued at $44,000. Virtu Financial LLC acquired a new stake in Trinity Biotech in the 3rd quarter valued at $51,000. Schonfeld Strategic Advisors LLC acquired a new stake in Trinity Biotech in the 2nd quarter valued at $76,000. Goldman Sachs Group Inc. acquired a new stake in Trinity Biotech in the 2nd quarter valued at $130,000. Finally, Morgan Stanley boosted its stake in Trinity Biotech by 31.2% in the 3rd quarter. Morgan Stanley now owns 251,317 shares of the company’s stock valued at $508,000 after buying an additional 59,816 shares in the last quarter. 30.29% of the stock is currently owned by institutional investors and hedge funds.

Trinity Biotech Company Profile (NASDAQ:TRIB)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

See Also: What is meant by holder of record?

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.